Qube Research & Technologies LTD Verve Therapeutics, Inc. Transaction History

Qube Research & Technologies LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$10.81 - $17.96 $357,973 - $594,745	33,115 New	33,115 $439,000
Q2 2023 Aug 14, 2023	SELL	$13.34 - $19.9 $336,421 - $501,858	-25,219 Reduced 71.15%	10,224 $191,000
Q1 2023 May 15, 2023	BUY	$14.3 - $24.01 $506,834 - $850,986	35,443 New	35,443 $511,000
Q2 2022 Aug 15, 2022	SELL	$11.14 - $23.17 $135,406 - $281,631	-12,155 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$20.92 - $39.36 $254,282 - $478,420	12,155 New	12,155 $277,000
Q3 2021 Nov 12, 2021	SELL	$46.0 - $73.99 $585,580 - $941,892	-12,730 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$31.92 - $60.25 $406,341 - $766,982	12,730 New	12,730 $767,000

186

73.3M

85K

215K

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $291M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.